Sign up Australia
Proactive Investors - Run By Investors For Investors

Alcidion Group takes e-health technology to ASX listing

Alcidion Group takes e-health technology to ASX listing

E-health provider Alcidion Group (ASX:ALC) has begun trading on the ASX boards today from the reverse takeover of the shell of Naracoota Resources, which last traded at $0.056 in December.

Alcidion has built an electronic software technology that centralises patient health data, including hospital pathology and oncology records onto mobile devices.

This consolidates clinical and patient data from multiple sources across hospitals into a single platform providing benefits to clinicians as well as better patient care to avoid medical errors.

The company earned $5 million in revenues in FY15 from deployment of the platform onto beta sites. It is already deployed at Western Health, Northern Territory Health, Tasmania Health and the Royal Melbourne.

Alcidion was founded by the former chairman and CEO of the South Australian Health Commission Ray Blight and Professor Malcolm Pradhan, and are looking to rapidly scale up its U.S. presence to take advantage of looming opportunities for health tech companies.

Well known technology entrepreneur Nathan Buzza is executive director of Alcidion. He was second-largest shareholder of listed clinical tech provider Azure Healthcare.

The shares were trading ahead on re-listing.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.



Register here to be notified of future ALC Company articles
View full ALC profile

Alcidion Group Timeline

Newswire
December 21 2015

Related Articles

test tubes in a laboratory
March 22 2017
It’s hived off its skin division, bolstered its board and has already won new business contracts worth €5.7mln so far this year
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
Microbes
April 16 2017
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use